In summary (Supplementary Fig. 5), the abundance of intratumoral CXCR5+CD8+T is associated with better OS and patients with TNM II + III disease whose tumor presented higher intratumoral CXCR5+CD8+T cells could benefit more from ACT. The gene discussed is CD8A; the disease is neoplasm.